



Published in final edited form as:

Adv Tech Biol Med. 2016 February ; 4(1): . doi:10.4172/2379-1764.1000157.

New Techniques for the Study of Neural Tube Defects

Yunping Lei¹ and Richard H Finnell^{1,2,*}

¹Dell Pediatric Research Institute, Department of Nutritional Sciences, The University of Texas at Austin, Austin, Texas

²Dell Children's Medical Center, Austin, Texas

Abstract

Neural tube defects (NTDs) are among the most common complex congenital malformations observed in newborns. When the neural tube fails to close completely, severe malformations of the brain and/or spinal cord and subsequent neurologic impairment occurs. It is widely believed that nutritional, environmental and genetic interactions contribute to NTDs. It is well established that low folate levels during pregnancy increases a mother's risk of having pregnancy complicated by an NTD, and providing periconceptional folate supplementation reduces this risk. The underlying genetic mechanisms of NTDs are still unclear. We review the many new approaches to better understand the etiology, especially the genetic etiology, underlying this family of birth defects.

Neural tube defects (NTDs) are characterized by a failure of neural tube closure during early embryonic development. The most frequent types of NTDs are spina bifida, which are defects of low spinal closure below the level of T12, and anencephaly, which results from incomplete closure of cranial neural tube. Failure of the neural folds to elevate results in the entire neural tube remaining open is referred to as craniorachischisis. The worldwide prevalence of NTDs is 0.5–1 per 1000 newborns, with variations among different populations [1]. The etiology of NTDs is complex, including both genetic and environment factors. In mice, so far there are more than 300 genes were linked to NTDs [2]. However, no causative mutations have been identified in humans to date. One possible reason is that there are very few large, multigenerational families that could be used to identify causative NTD genes using linkage mapping. Other obstacles to identifying NTD causative genes using mouse models is that most of these gene knockout models do not express an NTD phenotype as heterozygotes, yet the homozygous embryos most often suffer from *in utero* lethality.

In thinking about the genetic basis of NTDs, many investigators consider the notion that multiple, combined heterozygous variants in same gene, same pathway, genetic or physical interaction partner, work together to produce the NTD phenotype in humans. These combined functional variants could be inherited or result from germline *de novo* and/or somatic *de novo* mutations. However, it has been very difficult to directly test this

This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

*Corresponding author: Richard H. Finnell, Departments of Nutritional Sciences and Chemistry, The University of Texas at Austin, Dell Children's Medical Center, 1400 Barbara Jordan Blvd Austin, Texas, USA, Telephone: 512-495-3001; rfinnell@austin.utexas.edu.

hypothesis, due to the limitations of our existing genome editing technologies. Recently, the development of next generation sequencing (NGS) techniques [3] and clustered regularly interspaced short palindromic repeats (CRISPR)-Cas9 genetic editing technique [4] provide an excellent opportunity to test this hypothesis.

Next generation sequencing (NGS) also called (high throughput) massive parallel sequencing including NGS-whole exome sequencing (NGS-WES), NGS-whole genome sequencing (NGS-WGS), and NGS-target enrichment sequencing. Compared with first generation (Sanger) sequencing, the newer approaches can generate large amounts of sequencing data in a short time at a reasonably low cost. For example, the human genome sequencing project took 13 years and cost over \$3 billion dollars. Using the latest NGS equipment (eg. Illumina HiSeq 4000), sequencing a whole human genome can be completed in a week at a cost approaching \$1,000. Since more than 300 genes have been reported to be involved in murine neural tube closure, it is highly likely that even more genes that contribute to the expression of human NTDs will be discovered. We believe that one approach to identifying new candidate NTDs genes in humans, is to appropriate the NGS-WES and NGS-WGS methodologies/strategies that are currently being successfully used for identifying risk genes in autism spectrum disorder [5], a multifactorial disease similar to NTDs. For human NTDs, it is also assumed that multiple related (eg. in a pathway) functional variants combined can be the underlying genetic etiology of some cases. Thus far, millions of genetic variants have been identified; therefore, the potential combinations of multiple variants could be in the billions or trillions. To test whether combined rare variants in a pathway are human NTD genetic risk factors, scientists need to sequence thousands of NTD cases for all the known candidate pathway genes. The NGS-target enrichment sequencing technique is perfect for this purpose. Currently, there are three types of target capture/enrichment methods: multiple- PCR based method capture, hybrid capture (on-array or in-solution) and molecular inversion probes (MIP) capture [6]. Each method has its advantages and disadvantages. MIP has been successfully used for autism risk genes validation in a large sample size due to its low cost, ease of use, and template saving advantages [7]. We believe that this technique has the potential successfully enhance our understanding of NTDs risk genes/pathways by performing validation studies on large NTD cohorts.

The functional characterization of identified variants is important for judging whether the detected combination of variants is causative or not. The most direct way is to “knock-in” the variants into mice and then determine whether these variants induce an NTD phenotype, for murine neural tube closure shares much in common with human neural tube closure, perhaps more closely than neural tube closure in zebrafish or in *Xenopus*. The latest genetic editing technique, CRISPR-Cas9, can also be utilized for functional studies of identified gene variants. Compared with CRISPR-Cas9, traditional genetic editing techniques including homologous recombination, zinc finger nuclease, and transcription activator-like effector nuclease are laborious, expensive and time consuming. It usually takes 12–18 months to make a knock in mouse line. CRISPR-Cas9 technology can easily generate genetically modified mice in one month [8,9]. Recently, Zhong and colleagues used CRISPR-Cas9 technology to edit androgenetic haploid embryonic stem cells (AG-haESCs), and successfully injected the genetically modified AG-haESCs into MII oocytes that

developed into liveborn mouse pups [10]. The combination of these two new techniques working together should vastly improve our ability to perform the functional screening of human NTDs variants quickly and efficiently. Most of the identified variants in human NTDs are heterozygous mutations, such as the functional variants identified in planar cell polarity (PCP) pathway genes including: VANGL2 [11], VANGL1 [12], CELSR1 [13], SCRIB [14], LRP6 [15], FZD6 [16] and DISHEVELLED2 [17]. PCP single gene knock out heterozygotes do not produce an NTD phenotype in mice, while PCP double heterozygotes do result in multiple types of NTDs in mice [18]. Based on the mouse data, it is easy to hypothesize that a double loss of functional variants in PCP genes could also cause NTDs in human. To test this hypothesis, we need to screen a large number (thousands) of NTD samples for PCP genes using one of the aforementioned NGS-target enrichment techniques in order to identify those variants combinations. AG-haESCs could be used to make genetic “knock in” mice that contain the same variants combinations as observed in human NTD cases. Whether or not these “knock in” mice present with NTDs phenotype will be the hallmark by which to judge the NTD causality of these variant combinations. The same methods could also be used for other candidate NTD gene pathways, such as the sonic hedgehog pathway, one-carbon metabolism pathway, cilia pathway, cell apoptosis pathway, and more.

In summary, NGS, CRISPR-Cas9 and AG-haESCs are the state-of-art techniques and tools whose utilization will advance our understanding of the etiology of NTDs.

Acknowledgments

This work was supported in part with grant support from the National Institutes of Health [HD067244, NS076465, ES021390 and HD081216].

References

1. Wallingford JB, Niswander LA, Shaw GM, Finnell RH. The continuing challenge of understanding, preventing, and treating neural tube defects. *Science*. 2013; 339:1222002. [PubMed: 23449594]
2. Wilde JJ, Petersen JR, Niswander L. Genetic, epigenetic, and environmental contributions to neural tube closure. *Annu Rev Genet*. 2014; 48:583–611. [PubMed: 25292356]
3. Metzker ML. Sequencing technologies - the next generation. *Nat Rev Genet*. 2010; 11:31–46. [PubMed: 19997069]
4. Cong L, Ran FA, Cox D, Lin S, Barretto R, et al. Multiplex genome engineering using CRISPR/Cas systems. *Science*. 2013; 339:819–823. [PubMed: 23287718]
5. O’Roak BJ, Vives L, Girirajan S, Karakoc E, Krumm N, et al. Sporadic autism exomes reveal a highly interconnected protein network of de novo mutations. *Nature*. 2012; 485:246–250. [PubMed: 22495309]
6. Mamanova L, Coffey AJ, Scott CE, Kozarewa I, Turner EH, et al. Target-enrichment strategies for next-generation sequencing. *Nat Methods*. 2010; 7:111–118. [PubMed: 20111037]
7. O’Roak BJ, Vives L, Fu W, Egertson JD, Stanaway IB, et al. Multiplex targeted sequencing identifies recurrently mutated genes in autism spectrum disorders. *Science*. 2012; 338:1619–1622. [PubMed: 23160955]
8. Yang H, Wang H, Jaenisch R. Generating genetically modified mice using CRISPR/Cas-mediated genome engineering. *Nat Protoc*. 2014; 9:1956–1968. [PubMed: 25058643]
9. Ran FA, Hsu PD, Wright J, Agarwala V, Scott DA, et al. Genome engineering using the CRISPR-Cas9 system. *Nat Protoc*. 2013; 8:2281–2308. [PubMed: 24157548]

10. Zhong C, Yin Q, Xie Z, Bai M, Dong R, et al. CRISPR-Cas9-Mediated Genetic Screening in Mice with Haploid Embryonic Stem Cells Carrying a Guide RNA Library. *Cell Stem Cell*. 2015; 17:221–232. [PubMed: 26165924]
11. Lei YP, Zhang T, Li H, Wu BL, Jin L, et al. VANGL2 mutations in human cranial neural-tube defects. *N Engl J Med*. 2010; 362:2232–2235. [PubMed: 20558380]
12. Kibar Z, Torban E, McDearmid JR, Reynolds A, Berghout J, et al. Mutations in VANGL1 associated with neural-tube defects. *N Engl J Med*. 2007; 356:1432–1437. [PubMed: 17409324]
13. Lei Y, Zhu H, Yang W, Ross ME, Shaw GM, et al. Identification of novel CELSR1 mutations in spina bifida. *PLoS One*. 2014; 9:e92207. [PubMed: 24632739]
14. Lei Y, Zhu H, Duhon C, Yang W, Ross ME, et al. Mutations in planar cell polarity gene SCRIB are associated with spina bifida. *PLoS One*. 2013; 8:e69262. [PubMed: 23922697]
15. Lei Y, Fathe K, McCartney D, Zhu H, Yang W, et al. Rare LRP6 variants identified in spina bifida patients. *Hum Mutat*. 2015; 36:342–349. [PubMed: 25546815]
16. De Marco P, Merello E, Rossi A, Piatelli G, Cama A, et al. FZD6 is a novel gene for human neural tube defects. *Hum Mutat*. 2012; 33:384–390. [PubMed: 22045688]
17. De Marco P, Merello E, Consales A, Piatelli G, Cama A, et al. Genetic analysis of disheveled 2 and disheveled 3 in human neural tube defects. *J Mol Neurosci*. 2013; 49:582–588. [PubMed: 22892949]
18. Murdoch JN, Damrau C, Paudyal A, Bogani D, Wells S, et al. Genetic interactions between planar cell polarity genes cause diverse neural tube defects in mice. *Dis Model Mech*. 2014; 7:1153–1163. [PubMed: 25128525]